Should Californians Vote to Fund Cancer Research? Why They Should Think Twice.

Robert M. Kaplan distinguishes the value of immunotherapy from the merits of Proposition 38’s financing plan. He examines the measure’s debt burden, institution-specific funding rules, federal research spending and uncertain intellectual-property returns. Kaplan is a former NIH associate director, a Stanford senior scholar and co-chair of the No on Proposition 38 campaign.